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Ucma/GRP inhibits phosphate-
induced vascular smooth muscle 
cell calcification via SMAD-
dependent BMP signalling
Brecht A. Willems1,2, Malgorzata Furmanik1, Marjolein M. J. Caron  3, Martijn L. L. Chatrou1, 
Dennis H. M. Kusters1, Tim J. M. Welting3, Michael Stock4, Marta S. Rafael5, Carla S. B. Viegas5,6, 
Dina C. Simes5,6, Cees Vermeer2, Chris P. M. Reutelingsperger  1 & Leon J. Schurgers1
Vascular calcification (VC) is the process of deposition of calcium phosphate crystals in the blood 
vessel wall, with a central role for vascular smooth muscle cells (VSMCs). VC is highly prevalent in 
chronic kidney disease (CKD) patients and thought, in part, to be induced by phosphate imbalance. 
The molecular mechanisms that regulate VC are not fully known. Here we propose a novel role for 
the mineralisation regulator Ucma/GRP (Upper zone of growth plate and Cartilage Matrix Associated 
protein/Gla Rich Protein) in phosphate-induced VSMC calcification. We show that Ucma/GRP is present 
in calcified atherosclerotic plaques and highly expressed in calcifying VSMCs in vitro. VSMCs from Ucma/
GRP−/− mice showed increased mineralisation and expression of osteo/chondrogenic markers (BMP-2, 
Runx2, β-catenin, p-SMAD1/5/8, ALP, OCN), and decreased expression of mineralisation inhibitor MGP, 
suggesting that Ucma/GRP is an inhibitor of mineralisation. Using BMP signalling inhibitor noggin and 
SMAD1/5/8 signalling inhibitor dorsomorphin we showed that Ucma/GRP is involved in inhibiting the 
BMP-2-SMAD1/5/8 osteo/chondrogenic signalling pathway in VSMCs treated with elevated phosphate 
concentrations. Additionally, we showed for the first time evidence of a direct interaction between 
Ucma/GRP and BMP-2. These results demonstrate an important role of Ucma/GRP in regulating osteo/
chondrogenic differentiation and phosphate-induced mineralisation of VSMCs.
Vascular calcification (VC) is a process of deposition of calcium phosphate crystals in the form of hydroxyapatite 
in the intima and media of the vessel wall1,2. The presence of VC reduces arterial wall elasticity and alters the 
hemodynamic profile, increasing the risk of cardiovascular events. VC is an independent risk factor predicting 
cardiovascular mortality and frequently measured as marker of atherosclerotic burden3. Nearly all patients suf-
fering from cardiovascular disease have some degree of calcification, and in asymptomatic patients prevalence 
of coronary calcification corresponds with age. Amongst cardiovascular disease patients, approximately 60% of 
over 60-year-olds suffer from VC3,4. Chronic kidney disease (CKD) patients are known to be especially prone to 
VC. Mineral homeostasis dysregulation, uremic toxins and warfarin treatment are known to contribute to VC in 
dialysis patients5,6. Elevated phosphate in blood is thought to be one of the main inducers of VC in CKD7,8.
VC is an active process regulated by vascular smooth muscle cells (VSMCs). In response to cellular stress 
VSMCs undergo VC via several mechanisms: apoptosis, release of extracellular vesicles, loss of calcification inhib-
itors such as matrix Gla protein MGP; reviewed in Schurgers et al.9, ageing-related DNA damage and osteo/
chondrogenic differentiation10,11.
1Department of Biochemistry, School for Cardiovascular Diseases, Maastricht University, Maastricht, The 
Netherlands. 2VitaK BV, Maastricht University, Maastricht, The Netherlands. 3Department of Orthopedic Surgery, 
School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands. 4Department of 
Experimental Medicine I, Nikolaus-Fiebiger Centre of Molecular Medicine, University of Erlangen, Nuremberg, 
Germany. 5Centre of Marine Sciences (CCMAR), University of Algarve, Faro, Portugal. 6GenoGla Diagnostics, Centre 
of Marine Sciences (CCMAR), University of Algarve, Faro, Portugal. Brecht A. Willems and Malgorzata Furmanik 
contributed equally to this work. Correspondence and requests for materials should be addressed to L.J.S. (email: l.
schurgers@maastrichtuniversity.nl)
Received: 5 October 2017
Accepted: 9 March 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC RePoRts |  (2018) 8:4961  | DOI:10.1038/s41598-018-23353-y
In physiological conditions VSMCs exist in the vessel wall as contractile cells and regulate vascular tone. 
However, VSMCs are known to have a high degree of phenotypic plasticity12. In response to stress and injury, 
VSMCs lose expression of contractility-related genes such as SM22α, calponin (CNN1), and myosin light 
chain (MLC)13–16. When vascular injury is persistent, the phenotypic transition is dysregulated and VSMCs can 
undergo an unfavourable transdifferentiation into cells with characteristics of osteoblasts or chondrocytes4,12,17–20. 
This is termed osteo/chondrogenic differentiation. Many bone mineralisation-regulating proteins were found 
to be expressed in the calcifying blood vessel, such as BMP-2 Runx2, MGP, osteocalcin (OCN), osteopontin 
(OPN)18,21,22 amongst others and have been shown to play an active part in regulating VC. Additionally, calcifying 
VSMCs have been shown to release extracellular vesicles in a mechanism similar to release of matrix vesicles from 
chondrocytes23. However, the exact molecular mechanisms regulating VSMC osteo/chondrogenic transdifferen-
tiation are unknown.
Ucma (Upper zone of growth plate and Cartilage Matrix Associated protein; also known as Gla Rich Protein - 
GRP) is a novel mineralisation inhibitor, which was first reported in cartilage24,25 and later in the vasculature26,27. 
Ucma/GRP-deficient mice did not develop a clear phenotype28, however in vitro studies revealed that Ucma/
GRP regulates differentiation of chondrocytes and osteoblasts29–31. Using immunohistochemistry, Ucma/GRP 
was shown to be present at sites of VC. Moreover, when added exogenously, Ucma/GRP inhibited calcification of 
aortic rings in vitro26,27,29.
Based on the involvement of Ucma/GRP in differentiation of osteoblasts and its role in VC, we hypothe-
sized that Ucma/GRP is involved in osteo/chondrogenic differentiation of VSMCs. To test our hypothesis we 
examined expression of Ucma/GRP during phosphate-induced calcification of VSMCs. We also examined osteo/
chondrogenic gene expression and calcification of Ucma/GRP−/− VSMCs exposed to elevated levels of inorganic 
phosphate. Our findings indicate that Ucma/GRP reduces VC by inhibiting osteo/chondrogenic VSMC transdif-
ferentiation through a BMP-2-regulated pathway.
Results
Treatment of VSMCs in vitro with phosphate induces calcification. We first set out to examine 
calcification of primary mouse VSMCs in vitro. WT VSMCs were cultured in medium with elevated phosphate as 
described before8,32 (osteogenic medium, OM), which induced mineralisation in vitro, as observed by quantifica-
tion of deposited calcium phosphate crystals (Fig. 1A). To control for spontaneous mineral precipitation on colla-
gen, collagen-coated wells were incubated with OM in the absence of VSMCs. Under these a-cellular conditions, 
no calcification was observed (data not shown). To examine osteo/chondrogenic differentiation in mineralisation 
of VSMCs in vitro, Runx2 and Osteocalcin expression was measured using qPCR after 12 days of incubation with 
osteogenic medium (Fig. 1B and C). Expression of both markers was significantly increased, suggesting that the 
observed mineralisation is an active process involving osteo/chondrogenic differentiation. Moreover, treatment of 
human VSMC with osteogenic medium increased secretion of extracellular vesicles (Fig. 1D), which have recently 
been shown to mediate VC23.
Ucma/GRP is expressed in atherosclerotic plaques of ApoE−/− mice. Ucma/GRP has previously 
been shown to be expressed in calcified human aortas and aortic valves27. Here we demonstrated that Ucma/
GRP is expressed in advanced atherosclerotic lesions of ApoE−/− mice. UcmaGRP was expressed specifically in 
atherosclerotic plaques (Fig. 2A and B) in cells which show similarities to chondrocyte morphology. As shown 
in Fig. 2C and D, these cells also expressed osteo/chondrogenic markers BMP-2 and Runx2. This suggests that 
Ucma/GRP is involved in osteo/chondrogenic differentiation and calcification of VSMCs in atherosclerotic 
plaques. Interestingly, not all cells with chondrocyte-like morphology visibly expressed Ucma/GRP.
Figure 1. Increased phosphate concentrations induce calcification of mVSMCs in vitro. Cells were incubated 
with control medium (full growth medium, CM) or osteogenic medium (growth medium with 2.6 mM 
phosphate, OM) for 12 days. (A) Quantification of Ca content in mineralised mVSMC cultures, n = 4. (B,C) 
Calcification of mVSMCs was associated with increased expression of osteogenic genes Runx2 and osteocalcin 
measured by qPCR, n = 3. (D) Calcification of human VSMCs increased exosome secretion measured using 
a bead capture assay, n = 3. All graphs show mean + SD. Statistical significance was assessed using t-test. 
**p < 0.001–0.01, ***p < 0.001.
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Ucma/GRP expression in VSMCs in vitro increases in response to osteogenic medium. The pres-
ence of Ucma/GRP in murine VSMCs (mVSMCs) in vitro was confirmed using RT-PCR (Fig. 3A). Additionally, 
immunocytochemistry (Fig. 3B) has shown expression of Ucma/GRP in scattered cytoplasmic foci, which is 
consistent with its subcellular localization in other cell types31. Next, in order to examine whether Ucma/GRP has 
a role in mineralisation of VSMCs in vitro, expression was measured in response to treatment with osteogenic 
medium (Fig. 3C). Ucma/GRP expression, measured by qPCR, increased in a time-dependent manner with a 
20-fold increase after 12 days of culture. Immunocytochemistry analysis confirmed this result and showed that 
control medium does not induce a similar increase (Fig. 3D).
Ucma/GRP-deficient VSMCs are more prone to calcification in response to osteogenic 
medium. Aortas were harvested from Ucma/GRP−/− mice (KO) and wild type (WT) counterparts generated as 
previously described28. The knock-out of Ucma/GRP was confirmed by immunohistochemical staining of the epi-
physeal plate (Supplemental Fig. 1A). VSMCs were isolated and their identity was verified by immmunocytochem-
ical staining for VSMC markers (αSMA, CNN1, p-MLC) (Supplemental Fig. 1B). We and others26,27 have shown 
that Ucma/GRP is upregulated in response to calcification and that its expression is confined to osteo/chondro-
genic cells in atherosclerotic plaques (Figs 2A and 3A,B). Therefore, we hypothesized that Ucma/GRP is involved 
in controlling osteo/chondrogenic differentiation of VSMCs and consequently calcification. To test this, WT and 
Ucma/GRP−/− VSMCs were incubated in osteogenic medium over a time span of 15 days (Fig. 4A and B). Both 
WT and Ucma/GRP−/− VSMCs calcified in response to osteogenic medium, with calcification becoming detecta-
ble after 6 days. However, Ucma/GRP−/− VSMCs calcified approximately twice as much as WT cells after 9, 12 and 
15 days. Neither Ucma/GRP−/− nor WT VSMCs calcified in control medium (Supplemental Fig. 1C). Ucma/GRP 
knock-down in WT cells using siRNA resulted in significantly increased calcification compared to cells transfected 
Figure 2. Ucma/GRP is expressed in atherosclerotic plaques. Sections of atherosclerotic plaques from ApoE−/− 
mice fed a high fat diet for 12 weeks were stained for (A,B) Ucma/GRP, (C,D) BMP-2 and (E,F) Runx2. Arrows 
point to cells in the plaque with a chondrocyte-like morphology, which express both osteogenic markers and Ucma/
GRP; a – adventitia, i – intima, m – media. Scale bars are 200 µm in A, 100 µm in B, D, F and 250 µm in C and E.
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with a scramble control (Supplemental Fig. 1D), confirming that the observed effects are specific to Ucma/GRP. In 
response to osteogenic medium alkaline phosphatase (ALP) activity was increased in Ucma/GRP−/− cells but not 
in WT cells, suggesting increased osteo/chondrogenic potential of Ucma/GRP−/− cells (Fig. 4C).
Ucma/GRP deficiency results in increased osteo/chondrogenic gene expression. Since osteo/
chondrogenic differentiation is an important mechanism regulating VC and expression of osteo/chondrogenic 
markers is found in atherosclerotic plaques, we set out to examine whether there were any differences in osteo/
chondrogenic marker expression between WT and Ucma/GRP−/− VSMCs. We observed that Ucma/GRP−/− cells 
expressed increased levels of BMP-2 mRNA in baseline conditions (CM, Fig. 5A). Additionally, when challenged 
with osteogenic medium, Ucma/GRP−/− VSMCs expressed higher levels of OPN, Osteocalcin and BMP-2, com-
pared to WT VSMCs (Fig. 5A,B and C). MGP mRNA expression was significantly downregulated in Ucma/
Figure 3. Ucma/GRP expression is increased in calcifying mVSMCs. Cells were incubated in growth medium 
(CM) or osteogenic medium (OM) containing 2.6 mM phosphate. (A) RT PCR of Ucma/GRP in mouse 
chondrocytes and VSMCs. Bands represent several transcript variants of Ucma/GRP. (B) Immunocytochemical 
staining of Ucma/GRP in mouse VSMCs. Scale bars are 50 µm (top) and 20 µm (bottom) (C) QPCR 
quantification of Ucma/GRP expression in calcifying mVSMCs. Graph shows mean + SD, n = 4. Statistical 
significance was assessed using ANOVA. **p between 0.001–0.01. (D) Immunocytochemical staining of Ucma/
GRP in calcifying mVSMCs. Scale bars are 100 µm.
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GRP−/− compared to WT VSMCs, both in baseline and osteogenic conditions, in line with the increased calcifica-
tion potential of these cells (Fig. 5D). Upon treatment with osteogenic medium MGP expression increased, both 
in WT and Ucma/GRP−/− VSMCs. Western blot analysis demonstrated an increase in β-catenin and phosphoryl-
ated SMAD1/5/8 expression, suggesting the involvement of SMAD signalling pathways (Fig. 5E,F,G) known to be 
involved in osteoblast mineralization and VC. Additionally, expression of Runx2 and ALP was higher in Ucma/
GRP−/− cells compared to WT (Fig. 5E,H and I). Importantly, we also observed that Ucma/GRP−/− VSMCs dis-
played reduced expression levels of contractile phenotype marker αSMA compared to WT VSMCs (Supplemental 
Fig. 1E). Taken together these results show that Ucma/GRP−/− VSMCs undergo increased osteo/chondrogenic 
differentiation, compared to WT VSMCs, both at baseline as well as in osteogenic conditions.
The osteo/chondrogenic phenotype in Ucma/GRP−/− VSMCs is induced by lack of inhibition of 
a BMP-2/4-p-SMAD1/5/8-β-catenin dependent-pathway. BMP-2 is a key modulator in the develop-
ment of VC19,21. Since we observed an increase in BMP-2 expression and its downstream targets p-SMAD1/5/8, 
we investigated the involvement of BMP signalling in calcification of Ucma/GRP−/− VSMCs. We blocked BMP-2 
and BMP-4 signalling using noggin and treated VSMCs with osteogenic medium (Fig. 6A). Noggin treatment 
decreased calcification of both WT and Ucma/GRP−/− VSMCs. Additionally, to investigate whether there is 
an interaction between BMP-2/4 and Ucma/GRP we carried out co-immunoprecipitation using media from 
hVSMCs treated with BMP-2. BMP-2/4-containing protein complexes were captured with a BMP-2/4 antibody 
and analysed using western blotting for Ucma/GRP. The results show clearly the presence of Ucma/GRP (Fig. 6B), 
strongly pointing to a functional BMP-2/4-Ucma/GRP interaction. To examine whether there is a direct interac-
tion with BMP-2, we carried out solid phase binding assays by coating ELISA plates with carboxylated Ucma/GRP 
(cUcma), uncarboxylated (ucUcma), BMP-2 and MGP (positive control) and incubating with BMP-2 in the liquid 
phase. Detection of BMP-2 with an anti-BMP-2/4 antibody showed that BMP-2 bound to Ucma/GRP, specifically 
to the carboxylated Ucma/GRP form (Supplemental Fig. 2A).
Further to that, to investigate the involvement of specific downstream targets of BMP-2 we treated cells with 
dorsomorphin, an inhibitor of SMAD1/5/8 activation (AMPK inhibitor). Dorsomorphin decreased calcifi-
cation of WT VSMCS and restored levels of calcification in Ucma/GRP−/− cells to the levels observed in WT 
VSMCs (Fig. 6C). The reduction in calcification was reflected by a decrease in p-SMAD1/5/8 and ALP expression 
(Fig. 6D,E,F). Taken together, these results suggest that increased osteo/chondrogenic and calcification potential 
of Ucma/GRP−/− VSMCs is due to impaired inhibition of SMAD-dependent BMP signalling.
As Erk signalling has been known to also activate SMAD signalling33, we investigated whether inhibiting Erk 
phosphorylation has an effect on calcification of Ucma/GRP−/− VSMCs. Treatment of WT and Ucma/GRP−/− 
VSMCs with Erk phosphorylation inhibitor U0126 did not change calcification levels of cells of either genotype, 
suggesting that Erk phosphorylation and Ucma/GRP are not interacting to inhibit calcification of VSMC cultures 
(Supplemental Fig. 2B).
Discussion
VC is an important predictor of cardiovascular mortality. In particular, CKD patients have been shown to be at 
an increased risk of VC5,34. However, the mechanisms through which VC develops remain incompletely under-
stood. In the present study we demonstrate that Ucma/GRP plays a role in the attenuation of osteo/chondrogenic 
differentiation of VSMCs through a pathway involving SMAD-dependent BMP signalling. Osteo/chondro-
genic switching is accelerated in the absence of Ucma/GRP and this results in enhanced calcification. We also 
provide evidence that high phosphate concentrations, which is a common finding in CKD patients7, induce 
upregulation of Ucma/GRP in VSMCs. Our findings reveal a novel pathway through which Ucma/GRP inhibits 
phosphate-induced SMAD signalling and osteo/chondrogenic differentiation, thereby reducing the propensity 
for calcification of the vessel wall.
Figure 4. mVSMCs from Ucma/GRP−/− mice show increased calcification. Cells from Ucma/GRP−/− mice and 
WT counterparts were incubated with growth medium (CM) or osteogenic medium (OM) containing 2.6 mM 
phosphate. (A) Quantification of calcification over a 15 day period. Statistical significance was assessed using 
t-test, n = 3–5. (B) Alizarin red S staining of calcium deposited by mVSMCs after 12 days. Scale bar is 80 mm. 
(C) Alkaline phosphatase (ALP) in mVSMCs treated with osteogenic medium or control medium for 12 days. 
Statistical significance was assessed using ANOVA, n = 3. All graphs show mean + SD. *p between 0.05–0.01, 
**p between 0.001–0.01, ***p < 0.001.
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Ucma/GRP was previously shown to inhibit maturation of chondrocytes towards hypertrophic cells and oste-
ogenic differentiation of osteoblasts29. Ucma/GRP is known to be present in low levels in calcified aortic valves 
and in the media. Ucma/GRP inhibits calcification of aortic rings cultured in calcifying medium, when added 
exogenously to cultures, this was accompanied by an increase in αSMA expression and a decrease of osteopon-
tin expression27. In our study we confirmed the presence of Ucma/GRP in the vasculature and for the first time 
reveal that Ucma/GRP expression is markedly increased in osteo/chondrogenic cells in atherosclerotic plaques 
of ApoE−/− mice, which implicates its role in this vascular pathology. CKD patients show accelerated atheroscle-
rosis, which suggests that our in vivo findings are relevant for calcification in CKD-related atherosclerosis35,36.
BMP-2 is a potent inducer of calcification and regulator of osteo/chondrogenic differentiation of VSMCs, 
known to cause phosphate influx into cells21. BMP-2 acts by binding its cell surface receptors which transduce 
the signal to the cytoplasm by phosphorylating pathway-restricted SMADs (SMAD1 and SMAD5) for BMPs37. 
This leads to heterodimerization of pathway-restricted SMADs with SMAD4, a common-mediator SMAD, 
and translocation of the complex to the nucleus, where it binds directly to DNA38. As a result, changes in gene 
expression occur, such as upregulation of Runx2, OCN and ALP. Additionally, BMP-2 has been shown to induce 
accumulation of β-catenin39. β-catenin has been demonstrated to activate Runx2 expression in the context of 
phosphate-induced VSMC calcification40. BMP and Wnt pathways have been shown to be co-activated in calci-
fying VSMCs41, where SMAD1 and β-catenin interacted and regulated gene expression together. Additionally, 
dorsomorphin homologue 1 has been recently shown to inhibit phosphate-induced osteogenic differentia-
tion of hVSMCs by inhibiting BMP-242. Our data are in line with these findings, as we demonstrate increased 
Figure 5. Ucma/GRP−/− mVSMCs show increased expression of osteo/chondrogenic markers. Cells were 
treated with control (CM) or osteogenic medium (OM, with 2.6 mM phosphate) for 12 days. Panels (A–D) 
qPCR analysis of osteo/chondrogenic gene expression, n = 4–7. Statistical significance was assessed using t-test 
(Osteocalcin) or ANOVA (E) Western blotting analysis of osteo/chondrogenic markers. Both WT and KO cells 
were treated with OM. Figure shows full western blots obtained by cutting of a full-sized membrane prior to 
antibody incubations. Numbers in the middle show molecular weights of the protein standard. Numbers on the 
right show the expected molecular weights of the proteins. Panels F–I quantification of western blotting results 
from panel E, n = 3. Statistical significance was assessed using t-test. All graphs show mean + SD. *p between 
0.05–0.01, **p between 0.001–0.01.
www.nature.com/scientificreports/
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SMAD1/5/8 phosphorylation and expression of β-catenin, Runx2 and their downstream targets ALP, OCN and 
OPN in phosphate-treated Ucma/GRP−/− VSMCs. Here we demonstrate for the first time that Ucma/GRP inter-
acts with this BMP-SMAD signalling pathway by binding BMP-2 and that inhibiting BMP-2/-4 signalling with 
noggin and SMAD1/5/8 phosphorylation with dorsomorphin decreased calcification of VSMCs and osteo/chon-
drogenic gene expression. Interestingly, previous reports show that externally added BMP-2 decreased Ucma/
GRP expression in chondrocytes29, suggesting an interaction between BMP-2 signalling and Ucma/GRP. In addi-
tion to that, in osteoblasts Ucma/GRP is under direct transcriptional control of Runx2 and Osterix30, however this 
has not been investigated in VSMCs.
In our study we confirm that high levels of phosphate induce hallmarks of osteogenic differentiation in 
VSMCs, such as osteo/chondrogenic gene expression and extracellular vesicle release, and that Ucma/GRP 
expression is increased in VSMCs treated with osteogenic medium in vitro. This, together with the presence 
of Ucma/GRP in advanced atherosclerotic lesions, suggests that calcifying cells increase the expression of this 
inhibitor in a bid to protect themselves from adverse phenotype changes. This has been shown to happen with 
MGP, another vitamin K-dependent calcification inhibitor, by us in the present study and others43. Additionally, 
insufficient carboxylation of MGP due to warfarin administration is one of the factors contributing to VC in 
CKD44. Uncarboxylated Ucma/GRP, similar to uncarboxylated MGP, could contribute to these processes. Ucma/
GRP is a vitamin K-dependent protein, as it undergoes posttranslational carboxylation45. It has been previously 
shown that uncarboxylated Ucma/GRP accumulates at sites of pathological calcification in human aortic valves 
and media and only the carboxylated form of Ucma/GRP was able to inhibit calcification27. Our results are in line 
with this, as we show that carboxylated Ucma/GRP has high affinity to BMP-2, whereas uncarboxylated Ucma/
GRP binds BMP-2 only weakly. However, we have not investigated the carboxylation status of Ucma/GRP in the 
atherosclerotic plaques which we examined and this warrants further investigation.
MGP is known to inhibit VC by binding mineral and interacting with BMP-2, preventing it from binding its 
receptor7,9,23. It is therefore tempting to speculate that vitamin K-dependent inhibitors complement each other 
with respect to regulating VC: calcium-induced calcification is regulated by MGP and whereas phosphate-induced 
calcification is regulated by Ucma/GRP. This is further supported by previous studies showing that phosphate 
increases osteo/chondrogenic differentiation of VSMC in vitro, whereas this was not demonstrated for calcium 
yet8,12,46.
Figure 6. Ucma/GRP is involved in suppressing osteo/chondrogenic differentiation by interacting with BMP-2. 
(A) Quantification of calcification deposited by mVSMCs incubated with 100 ng/ml noggin in the presence of 
osteogenic medium (2.6 mM phosphate) for 12 days, n = 6. Statistical significance was assessed using ANOVA. 
(B) Conditioned media from hVSMCs treated with 500 ng/ml of BMP-2 for 24 h was used to capture BMP-2-
containing protein complex by Co-immunoprecipitation (Co-IP) with a BMP2/4 antibody, and the presence 
of BMP2 and GRP in the eluted complex was detected by western blot. Two bands (25 kDa and 15 kDa) 
correspond to the dimeric and monomeric BMP-2/4. Representative image of 3 independent experiments. 
(C) Quantification of calcification deposited by mVSMCs from Ucma/GRP KO and WT mice, n = 8. Cells 
were incubated with 2 µM dorsomorphin in osteogenic medium (OM) for 12 days. Statistical significance was 
assessed using ANOVA. (D) Western blotting analysis of phosphorylated SMAD 1/5/8 and ALP and in Ucma/
GRP−/− mVSMCs treated with 2 µM dorsomorphin in osteogenic medium (OM) for 12 days. Figure shows 
full western blots obtained by cutting of a full-sized membrane prior to antibody incubations. Numbers in the 
middle show molecular weights of the protein standard. Numbers on the right show the expected molecular 
weights of the proteins. (E,F) Quantification of Western blots from panel C, n = 3. Statistical significance was 
assessed using t-test. All graphs show mean + SD. *p between 0.05–0.01, **p between 0.001–0.01, ***p < 0.001.
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Based on our observations, we propose a model of how Ucma/GRP inhibits VC (Fig. 7). When VSMCs are 
exposed to elevated phosphate concentrations in the extracellular environment, as is the case in CKD patients, 
osteo/chondrogenic differentiation (as evidenced by increased Runx2, β-catenin, osteocalcin, osteopontin and ALP 
expression) is initiated via increased BMP-2-SMAD signalling. We propose that Ucma/GRP can ameliorate the 
effect of increased phosphate by inhibiting this signalling pathway and thus reduce calcification of the vessel wall.
Taken together, we demonstrate that Ucma/GRP, a member of a range of inherent calcification inhibitors 
present in the vasculature47, plays an important role in regulating osteo/chondrogenic differentiation of VSMCs. 
Our findings have implications for vascular pathologies which lead to VC and represent an advancement in 
our knowledge about the steps resulting in VC. One of the main goals in the treatment of patients with CKD is 
to reduce the substantially increased risk of cardiovascular comorbidity and mortality, improving both quality 
and length of life. The increase in CKD stage and cardiovascular risk is accompanied by increased phosphate 
levels. As shown by our results, the phosphate-Ucma/GRP-BMP axis holds promise for novel interventions. 
Pharmacological manipulation of Ucma/GRP levels could represent a novel therapeutic strategy to prevent VC.
Methods
Experimental animals. Ucma/GRP−/− C57BL\6 mice were generated and kindly provided by Dr. M. 
Stock, University of Erlangen, Germany, with the approval of the local ethics authorities (University of Erlangen-
Nuremberg and the Government of Mittelfranken, Ansbach, Germany) and according to the regulations of the 
animal facilities in Germany28. Mice were maintained in a specific pathogen-free environment with free access to 
water and western type diet (Arie Block, Woerden, the Netherlands) and sacrificed by portal vein puncture after 
12 weeks. Aortas were harvested for immunohistochemistry and VSMC isolation.
Immunohistochemistry. Aortic sections of atherosclerotic ApoE−/− mice from a previous study were 
used48. Sequential 4 µm paraffin sections were cut from the aortic arch and used for immunohistochemical stain-
ing as previously described48. The following antibodies were used: anti- BMP-2 (Santa Cruz, sc-6895), anti-Runx2 
(M70, Santa Cruz, sc-10758) anti-total Ucma/GRP antibody (Cterm-GRP, GenoGla Diagnostics, Faro, 
Portugal), HRP conjugated secondary antibodies and DAB or Nova-RED substrate (Vector Labs, Amsterdam, 
the Netherlands). Sections were counterstained with haematoxylin (Klinipath, Duiven, the Netherlands) and 
mounted in entellan (Merck, Amsterdam, the Netherlands).
VSMC isolation and culture. Endothelium and adventitia were removed from aortas of Ucma/GRP−/− 
and WT littermates. Tissue was dissected into ± 5 mm² pieces and digested with 3 mg/ml collagenase (Sigma, 
Zwijndrecht, the Netherlands) and 1 mg/ml elastase (Sigma) for 4 hours at 37 °C in DMEM (Gibco, Bleiswijk, 
the Netherlands). The cells were washed, resuspended in growth medium (DMEM with 10% FCS, Gibco, 100 U/
ml penicillin and 100 mg/ml streptomycin, Gibco) and transferred to culture dishes. Success of the isolation was 
determined by immunofluorescent staining for αSMA, SM22α, phosphorylated myosin light chain 2 (method 
below) and western blotting for αSMA. Cells at passage 4–12 were used for experiments. Cells were maintained 
in culture medium and passaged when 90% confluent. Cell cultures were not supplemented with additional vita-
min K. The following inhibitors were added to media for treatments: 2 µM of U0126 (Merck, Amsterdam, the 
Netherlands), 100 ng/ml noggin (R&D systems, Abingdon, United Kingdom), 2 µM dorsomorphin dihydrochlo-
ride (sc-361173, Santa Cruz). All inhibitors were added to cells for the full duration of the experiment, as indi-
cated in figure legends. Medium was refreshed every 2–3 days.
Figure 7. Proposed model of the protective effect of Ucma/GRP in calcifying mVSMCs. Ucma/GRP expression 
is increased as a negative feedback loop mechanism when extracellular phosphate is elevated. Ucma/GRP 
prevents activation of phosphate-induced BMP-2-SMAD signalling in calcifying VSMCs, acting as an inhibitor 
of signalling cascades that lead to calcification. OCN – osteocalcin, OPN – osteopontin, ALP – alkaline 
phosphatase, MGP – matrix Gla protein.
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Human primary VSMCs (hVSMCs) were used for exosome quantification assay and co-immunoprecipitation. 
They were maintained in M199 with 20% FCS, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco).
Immunofluorescence. Cells were fixed with 4% PFA, permeablilised with 0.1% Triton X-100, blocked 
in 1% BSA/PBS and incubated with primary antibodies (Calponin, Abcam, ab46794; αSMA,Sigma; phospho-
rylated myosin light chain 2, Cell Signalling, 3675S and anti-total Ucma/GRP antibody (Cterm-GRP, GenoGla 
Diagnostics, Faro, Portugal). The following secondary antibodies were used: anti-rabbit-FITC (Dako, F0205) 
and anti-mouse-FITC (Dako, F0232). Nuclei were stained with DAPI (Sigma–Aldrich). Cells were mounted in 
a glycerol DABCO mounting medium. Pictures were taken with a Leica DM2000 widefield microscope (Leica 
Microsystems).
Calcification assays. 4 × 104 cells were seeded per well of a 12-well plate. After 24 hours medium was 
changed to osteogenic medium (growth medium +2.6 mM PO43−, OM) or growth medium (control medium, 
CM). Quantification of deposited calcium was carried out using a calcium determination kit (Randox, London, 
United Kingdom) according to the manufacturer’s instruction, after solubilising mineral deposits in 0.1 M HCl. 
Calcium measurements were normalised to protein content using micro BCA assay (Thermo Scientific, Bleiswijk, 
the Netherlands). Calcification was additionally visualised using Alizarin Red S staining adapted from Gregory 
et al.49.
RNA isolation and quantitative real-time PCR. Total RNA was isolated using TRI Reagent (Sigma). RNA 
concentration and quality were determined using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Bleiswijk, 
the Netherlands) and agarose-denaturing gel electrophoresis. 1 µg of total RNA was treated with DNAse I (Promega, 
Leiden, the Netherlands) and reverse transcribed using M-MLV reverse transcriptase (Invitrogen, Bleiswijk, the 
Netherlands), an oligo dT adapter (Eurogentec, Maastricht, the Netherlands) and RNAse Out (Invitrogen, Bleiswijk, 
the Netherlands). Real-time qPCR was performed using the Quantitect SYBR green PCR kit (Qiagen, Venlo, the 
Netherlands) in a LightCycler 480 II (Roche, Woerden, the Netherlands) with 50 ng of cDNA and 0.5 µM of each 
primer. The following primers were used BMP-2 (F) GTG-CTT-CTT-AGA-CGG-ACT-GCG-GTC-TCC-TA, 
BMP-2 (R) GCC-TGA-GTG-CCT-GCG-GTA-CAG-ATC-TAG, Runx2 (F) GAC-GAG-GCA-AGA-GTT-TCA-CC, 
Runx2 (R) GGA-CCG-TCC-ACT-GTC-ACT-TT, HPRT1 (F) AGC-CAA-ATA-CAA-AGC-CTA-AGA-TGA-GCG, 
HPRT1 (R) GAA-ATG-TCA-GTT-GCT-GCG-TCC-CCA-GA, MGP (F) ACA-CAG-AGG-CAG-ACT-CAC- 
AGG-ACA-CCC, MGP (R) CTG-AGG-GGA-CAT-AAA-GGT-GTT-GGC-AT, OCN (F) AAG-CAG-GAG-GGC- 
AAT-AAG-GT, OCN (R) TTT-GTA-GGC-GGT-CTT-CAA-GC, OPN (F) TGA-CCA-CAT-GGA-CGA-CGA- 
TGA-TGA-CGA-TGA, OPN (R) GGG-ACG-ATT-GGA-GTG-AAA-GTG-TCT-GCT-TGT. Fluorescence curves 
were analyzed with LightCycler 480 Software (Version 1.5) and relative quantification was performed with the 2−ΔΔCt 
method. Ucma/GRP was detected as described previously45. All samples were assayed in triplicate.
Quantification of exosome release. Exosomes were quantified using a bead-capture assay as described 
before23. Briefly, anti-human CD63 antibody (556019, BD Bioscience) was immobilized on aldehyde-sulfate func-
tionalized beads (Invitrogen). Human primary VSMC culture media was incubated with anti-CD63-coated beads 
on a shaker overnight at 4 °C. VSMCs were stained with Hoechst 33342 (Thermo Fisher) and counted using a 
Cytation 3 live-cell imager. Beads were washed and incubated with anti-CD81-PE antibodies for 1 h at room 
temperature. Then beads were washed with PBS with 2% BSA and analyzed by flow cytometry (Accuri C6, BD). 
Arbitrary units (AU) were calculated as mean fluorescence units times percentage of positive beads and normal-
ized to the number of cells.
Western blotting. VSMCs were lysed in 0.1 M Tris pH 8.1, 0.15 M NaCl, 1% triton x-100 0.2 mM NaVO3 
and 1:50 protease inhibitor cocktail (Sigma). Protein concentrations were determined using DC protein assay 
(Bio-Rad, Veenendaal, the Netherlands) and lysates were separated on Any kD Mini-PROTEAN TGX Precast 
Protein Gels (BioRad). Samples were transferred to a PVDF or nitrocellulose membrane (BioRad) and incu-
bated overnight with anti-αSMA (A2547, Sigma), anti-calponin (ab46794, Abcam), anti-ALP (R&D Systems, 
AF290), anti-Runx2 (MBL, D130-3), anti-β-catenin (BD, 610153), anti-p-SMAD1/5/8 (Cell Signalling, 12820P) 
and α-tubulin (Sigma, T6074) antibodies. Protein was then detected using HRP-conjugated secondary anti-
bodies (anti-mouse: p0447, Dako; anti-rabbit: 7074S, Cell Signalling, anti-goat: P0449, Dako) and visualized by 
enhanced chemiluminescence (Pierce ECL Western Blotting Substrate, ThermoFisher Scientific).
Co-immunoprecipitation. Co-IP assays were performed using conditioned media from hVSMCs cul-
tured in the presence of 500 ng/ml of recombinant BMP-2 (Preprotech) for 24 h in M199 with 10% FBS, and the 
Dynabeads Co-immunoprecipitation Kit (Novex, Life Technologies), according to manufacturer’s recommenda-
tions. The BMP-2/4 monoclonal (Santa Cruz Biotechnology, sc-137087) and negative IgG antibodies were used as 
capture antibodies in the Co-IP reactions, and Western blot analysis of the eluted proteins were performed using 
CTerm-Ucma/GRP (GenoGla Diagnostics, Faro, Portugal) and BMP-2/4 antibodies as described above.
Alkaline phosphatase activity. Cells were lysed in 1% Triton X-100 in PBS, subjected to 2 freeze-thaw 
cycles and centrifuged at 13000 g for 5 minutes. ALP activity in the supernatants was measured at 405 nm using 
4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma) as substrate. Enzyme activity (U) was normalised 
to protein concentrations.
www.nature.com/scientificreports/
1 0SCIENTIFIC RePoRts |  (2018) 8:4961  | DOI:10.1038/s41598-018-23353-y
Statistical analysis. Data shown are mean ± SD. All data were verified in ≥3 independent experiments. 
Statistical analysis was performed by 1-way ANOVA with Bonferroni post hoc test or Student’s t-test, as stated 
in figure legends, using PRISM software (GraphPad). Values of P < 0.05 were considered statistically significant.
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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